Sage Journals: Discover world-class research

Abstract

High expression levels of telomerase reverse transcriptase messenger RNAs in differentiated cells can be used as a common marker for cancer development. In this paper, we describe a novel computational method for selection of allosteric ribozymes that sense a specific sequence of human telomerase reverse transcriptase mRNAs. The in silico selection employed is based on computing secondary structures of RNA using the partition function in combination with a random search algorithm. We selected one of the ribozymes for experimental validation. The obtained results demonstrate that the tested ribozyme has a high-speed (∼1.8 per minute) of self-cleavage and is very selective. It can distinguish well between perfectly matching effector and the closest expressed RNA sequence in the human cell with 10 mismatches, with a ∼300-fold difference under physiologically relevant conditions. The presented algorithm is universal since the allosteric ribozymes can be designed to sense any specific RNA or DNA sequence of interest. Such designer ribozymes may be used for monitoring the expression of mRNAs in the cell and for developing novel anticancer gene therapies.

Get full access to this article

View all access options for this article.

References

AUBERT

, and LANSDORP

P.M.

(2008). Telomeres and aging. Physiol. Rev., 88, 557–579.

BLACKBURN

E.H.

(2005). Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett., 579, 859–862.

BLOUNT

, PUSKARZ

, PENCHOVSKY

, and BREAKER

(2006). Development and application of a high-throughput assay for glmS riboswitch activators. RNA Biol., 3, 77–81.

GRUBER

A.R.

, LORENZ

, BERNHART

S.H.

, NEUBOCK

, and HOFACKER

I.L.

(2008). The Vienna RNA websuite. Nucleic Acids Res., 36, W70–74.

GUO

, HAQUE

, HALLAHAN

, REIF

, and LI

(2012). Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther., 22, 226–245.

HANAHAN

, and WEINBERG

R.A.

(2000). The hallmarks of cancer. Cell 100, 5770.

HARLEY

C.B.

(2008). Telomerase and cancer therapeutics. Nat. Rev. Cancer, 8, 167–179.

HAYFLICK

, and MOORHEAD

P.S.

(1961). The serial cultivation of human diploid cell strains. Exp. Cell Res., 25, 585–621.

HENSON

J.D.

, NEUMANN

A.A.

, YEAGER

T.R.

, and REDDEL

R.R.

(2002). Alternative lengthening of telomeres in mammalian cells. Oncogene, 21, 598–610.

10.

HINDLE

K.S.

, KIRKPATRICK

, and MOKBEL

2002. Correspondence re: Sek, et al. Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin. Cancer Res., 7: 1976–1981, 2001. Clin Cancer Res 8, 628–629.

11.

ITO

, KYO

, KANAYA

, TAKAKURA

, KOSHIDA

, NAMIKI

, and INOUE

(1998). Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin. Cancer Res., 4, 2807–2810.

12.

KLAUSER

, and HARTIG

J.S.

(2013). An engineered small RNA-mediated genetic switch based on a ribozyme expression platform. Nucleic Acids Res, 41, 5542–5552.

13.

KONG

D.S.

, CARR

P.A.

, CHEN

, ZHANG

, and JACOBSON

J.M.

(2007). Parallel gene synthesis in a microfluidic device. Nucleic Acids Res. 35, e61.

14.

MATHEWS

D.H.

, SABINA

, ZUKER

, and TURNER

D.H.

(1999). Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol., 288, 911–940.

15.

MCCASKILL

J.S.

(1990). The equilibrium partition function and base pair binding probabilities for RNA secondary structure. Biopolymers, 29, 1105–1119.

16.

OKADA

, WATANABE

, OHTSUBO

, MOURI

, YAMAGUCHI

, MOTOO

, and SAWABU

(2012). Multiple factors influencing the release of hTERT mRNA from pancreatic cancer cell lines in in vitro culture. Cell Biol. Int., 36, 545–553.

17.

OSBORNE

E.M.

, SCHAAK

J.E.

, and DEROSE

V.J.

(2005). Characterization of a native hammerhead ribozyme derived from schistosomes. RNA, 11, 187–196.

18.

PENCHOVSKY

(2012a). Engineering gene control circuits with allosteric ribozymes in human cells as a medicine of the future. In: Quality Assurance in Healthcare Service Delivery, Nursing and Personalized Medicine: Technologies and Processes. Lazakidou

and Daskalaki

, eds. (IGI Global), pp. 71–92.

19.

PENCHOVSKY

(2012b). Engineering integrated digital circuits with allosteric ribozymes for scaling up molecular computation and diagnostics. ACS Synth. Biol., 1, 471–482.

20.

PENCHOVSKY

(2013a). Computational Design and Biochemical Probing of Allosteric Ribozymes as Molecular Biosensors. Nat. Protoc In Press.

21.

PENCHOVSKY

(2013b). Computational design and biosensor applications of small molecule-sensing allosteric ribozymes. Biomacromolecules, 14, 1240–1249.

22.

PENCHOVSKY

(2013c). Present and future RNA-based approaches to medical genomics. International Journal of Genomic Medicine In Press.

23.

PENCHOVSKY

(2013d). Programmable and automated bead-based microfluidics for versatile DNA microarrays under isothermal conditions. Lab Chip, 13, 2370–2380.

24.

PENCHOVSKY

, and BREAKER

R.R.

(2005). Computational design and experimental validation of oligonucleotide-sensing allosteric ribozymes. Nat. Biotechnol., 23, 1424–1433.

25.

PENCHOVSKY

, and STOILOVA

C.C.

(2013). Riboswitch-based antibacterial drug discovery using high-throughput screening methods. Expert Opin. Drug Discov., 8, 65–82.

26.

PHATAK

, and BURGER

A.M.

(2007). Telomerase and its potential for therapeutic intervention. Br. J. Pharmacol., 152, 1003–1011.

27.

PIGANEAU

, THUILLIER

, and FAMULOK

(2001). In vitro selection of allosteric ribozymes: theory and experimental validation. J. Mol. Biol., 312, 1177–1190.

28.

POOLE

J.C.

, ANDREWS

L.G.

, and TOLLEFSBOL

T.O.

(2001). Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene, 269, 1–12.

29.

QIAN

, and WINFREE

(2011). A simple DNA gate motif for synthesizing large-scale circuits. J. R. Soc. Interface, 8, 1281–1297.

30.

RANKIN

A.M.

, FALLER

D.V.

, and SPANJAARD

R.A.

(2008). Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. Anticancer Drugs, 19, 329–338.

31.

SEKI

, SUDA

, AOYAGI

, SUGAWARA

, NATSUI

, MOTOYAMA

, SHIRAI

, SEKINE

, KAWAI

, MITA

, et al. (2001). Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin. Cancer Res., 7, 1976–1981.

32.

SHAY

J.W.

, and KEITH

W.N.

(2008). Targeting telomerase for cancer therapeutics. Br. J. Cancer, 98, 677–683.

33.

SMOGORZEWSKA

, and DE LANGE

(2004). Regulation of telomerase by telomeric proteins. Annu. Rev. Biochem., 73, 177–208.

34.

TANG

, and BREAKER

R.R.

(1997). Rational design of allosteric ribozymes. Chem. Biol., 4, 453–459.

35.

TINSLEY

R.A.

, FURCHAK

J.R.

, and WALTER

N.G.

(2007). Trans-acting glmS catalytic riboswitch: locked and loaded. RNA, 13, 468–477.

36.

WAGURI

, SUDA

, NOMOTO

, KAWAI

, MITA

, KUROIWA

, IGARASHI

, KOBAYASHI

, FUKUHARA

, and AOYAGI

(2003). Sensitive and specific detection of circulating cancer cells in patients with hepatocellular carcinoma; detection of human telomerase reverse transcriptase messenger RNA after immunomagnetic separation. Clin. Cancer Res., 9, 3004–3011.

37.

WANG

R.C.

, SMOGORZEWSKA

, and DE LANGE

(2004). Homologous recombination generates T-loop-sized deletions at human telomeres. Cell, 119, 355–368.

38.

YEN

, SVENDSEN

, LEE

J.-S.

, GRAY

J.T.

, MAGNIER

, BABA

, D'AMATO

R.J.

, and MULLIGAN

R.C.

(2004). Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature, 431, 471–476.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.17 MB

0.10 MB

0.09 MB

0.02 MB

Computational Selection and Experimental Validation of Allosteric Ribozymes That Sense a Specific Sequence of Human Telomerase Reverse Transcriptase mRNAs as Universal Anticancer Therapy Agents

Abstract

Get full access to this article

References

Supplementary Material